Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Epub 2020 Jan 16.
In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at the ESMO Asia Meeting in November 2018, by both the ESMO and the Korean Society of Medical Oncology (KSMO), to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the latest ESMO 2019 guidelines to take into account the ethnic and geographical differences associated with the treatment of early breast cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with early breast cancer representing the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO) Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices, and the drug availability and reimbursement situations, in the individual participating Asian countries.
鉴于 2015 年发布的最新版欧洲肿瘤内科学会（ESMO）原发性乳腺癌诊断、治疗和随访临床实践指南计划进行新版修订，2018 年 11 月 ESMO 亚洲会议上，ESMO 和韩国肿瘤学会（KSMO）决定于 2019 年在首尔召开一次专门的面对面指南会议。目的是使最新的 2019 年 ESMO 指南适应亚洲患者接受早期乳腺癌治疗相关的人种和地域差异。这些指南代表了来自韩国（KSMO）、中国（CSCO）、印度（ISMPO）、日本（JSMO）、马来西亚（MOS）、新加坡（SSO）和中国台湾（TOS）肿瘤学会的早期乳腺癌治疗专家的共识意见。投票是基于科学证据进行的，既独立于各参与亚洲国家的当前治疗实践，也独立于药物的可及性和报销情况。
